CARDIOME PHARMA CORP (CRME) reported quarterly earnings results on Friday, May-13-2016. The company said it had a profit of $-0.06 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.15. Analysts had a consensus of $-0.21. The company posted revenue of $7.09 million in the period, compared to analysts expectations of $6.22 million. The company’s revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.23 EPS.
CARDIOME PHARMA CORP closed down -0.07 points or -1.40% at $4.94 with 56,860 shares getting traded on Tuesday. Post opening the session at $5.01, the shares hit an intraday low of $4.84 and an intraday high of $5.15 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is focused on the development and commercialization of cardiovascular therapies that improve the life and health of patients suffering from heart disease. The Company has two marketed in-hospital cardiology products BRINAVESSTM and AGGRASTAT which are commercially available in markets outside of the United States. BRINAVESSTM (vernakalant (IV)) is approved in the European Union and is registered and approved in approximately 50 countries for the conversion of onset atrial fibrillation to sinus rhythm in adults (for non-surgery patients with atrial fibrillation of seven days or less) and for use in post-cardiac surgery patients with atrial fibrillation of three days or less. AGGRASTAT (tirofiban HCL) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in Acute Coronary Syndrome patients.